Ipilimumab - CAS 477202-00-9
Catalog number: 477202-00-9
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C6742H9972N1732O2004S40
COA:
Inquire
Targets:
CTLA4
Description:
Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
A recombinant human immunoglobulin (Ig) G1 that binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation.
Synonyms:
BMS-734016 MDX-010
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Milli-Grams
Current Developer:
Bristol-Myers Squibb; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical; University of Texas M. D. Anderson Cancer Center
1.Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen Studie.
Huebner J1, Mohr P2, Simon JC3, Fluck M4, Berking C5, Zimmer L6, Loquai C7. J Dtsch Dermatol Ges. 2016 May;14(5):508-13. doi: 10.1111/ddg.12750_g.
HINTERGRUND UND ZIEL: In Deutschland wenden 40-90 % aller Krebspatienten Methoden der komplementären and alternativen Medizin (KAM) an. Bis dato gibt es kein Datenmaterial zum Einsatz der KAM bei Melanompatienten. Das Ziel unserer Studie war es, Daten über den Gebrauch, die Informationsquellen und Ziele von Patienten mit metastasierendem Melanom zu erfassen.
2.Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial.
Huebner J1, Mohr P2, Simon JC3, Fluck M4, Berking C5, Zimmer L6, Loquai C7. J Dtsch Dermatol Ges. 2016 May;14(5):508-13. doi: 10.1111/ddg.12750.
BACKGROUND AND OBJECTIVES: In Germany, 40-90 % of all cancer patients use complementary and alternative medicine (CAM). So far, no data are available on the use of CAM by melanoma patients. The objective of our study was to gather data on CAM use, sources of information, and goals of patients with metastatic melanoma.
3.Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
Harries M1, Malvehy J2, Lebbe C3, Heron L4, Amelio J5, Szabo Z6, Schadendorf D7. Eur J Cancer. 2016 Apr 22. pii: S0959-8049(16)00049-6. doi: 10.1016/j.ejca.2016.01.011. [Epub ahead of print]
AIMS AND BACKGROUND: With the recent emergence of immunotherapies and novel targeted treatments for advanced and metastatic melanoma such as selective B-Raf inhibitors and checkpoint inhibitors, the treatment landscape in Europe has changed considerably. The aim of this review was to provide an overview of current treatment pathways in Europe for the treatment of advanced melanoma, unresectable stage III-IV.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CTLA4 Products


MK-0668 mesylate
(CAS: 865111-04-2)

MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino subst...

Tremelimumab
(CAS: 745013-59-6)

A human immunoglobulin (Ig) G2 monoclonal antibody directed against the human T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4), with ...

CAS 865110-07-2 MK-0668

MK-0668
(CAS: 865110-07-2)

MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino subst...

CAS 477202-00-9 Ipilimumab

Ipilimumab
(CAS: 477202-00-9)

Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)...

Chemical Structure

CAS 477202-00-9 Ipilimumab

Quick Inquiry

Verification code

Featured Items